Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge

Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Kathleen M. Neuzil, Allison August, Heather Clouting, Gabrielle Fortier, Weiping Deng, Shu Han, Xiaoping Zhao, Brett Leav, Carla Talarico, Bethany Girard, Yamuna D. Paila, Joanne E. Tomassini, Florian Schödel, Rolando Pajon, Honghong Zhou, Rituparna Das, Jacqueline Miller
doi: https://doi.org/10.1101/2021.09.17.21263624
Lindsey R. Baden
1Brigham and Women’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hana.elsahly@bcm.edu
Hana M. El Sahly
2Baylor College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hana.elsahly@bcm.edu
Brandon Essink
3Meridian Clinical Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Follmann
4National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Neuzil
5University of Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison August
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Clouting
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabrielle Fortier
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiping Deng
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu Han
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoping Zhao
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Leav
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Talarico
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany Girard
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yamuna D. Paila
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne E. Tomassini
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Schödel
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolando Pajon
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Honghong Zhou
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rituparna Das
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Miller
6Moderna, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Following emergency use authorization in December 2020, the Coronavirus Efficacy (COVE) trial was amended to an open-label phase, where participants were unblinded and those randomized to placebo were offered vaccination. Emergence of the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with increased incidences of coronavirus disease 2019 (Covid-19) among unvaccinated and vaccinated persons. This exploratory analysis evaluated the incidence and genetic sequences of Covid-19 cases in the ongoing COVE trial during the open-label phase, with a focus on July-August 2021, when delta-variants surged in the US.

Methods Covid-19 cases were identified in participants initially randomized to mRNA-1273 (vaccinated from July-December 2020) and those initially randomized to the placebo (vaccinated December 2020-April 2021) who received at least one dose and were SARS-CoV-2-negative at baseline in the modified-intent-to-treat population were analyzed. Included were Covid-19 cases occurring after 26-Mar-2021 with positive RT-PCR results in nasopharyngeal samples (central lab test) and reported Covid-19 symptoms. Genetic sequencing of Covid-19 cases was also performed.

Results There were 14,746 participants in the earlier mRNA-1273 (mRNA-1273e) group and 11,431 in the later placebo-mRNA1273 (mRNA-1273p) group. Covid-19 cases increased from the start of the open-label phase to July-August 2021. During July and August, 162 Covid-19 cases occurred in the mRNA-1273e group and 88 in the mRNA-1273p group. Of the cases sequenced, 144/149 [97%]) in the mRNA-1273 and 86/88 (99%) in the mRNA-1273p groups were attributed to delta. The incidence rate of Covid-19 was lower for the mRNA-1273p (49.0/1000 person-years) versus mRNA-1273e (77.1/1000 person-years) group [36.4% (95% CI 17.1%-51.5%) reduction]. There were fewer severe Covid-19 cases in the mRNA-1273p (6; 6.2/1000 person-years) than mRNA-1273e (13; 3.3/1000 person-years) [46.0% (95% CI −52.4%-83.2%) reduction]. Three Covid-19 related hospitalizations occurred with two resulting deaths in the mRNA-1273e group.

Conclusion Incidence rates of Covid-19 and severe Covid-19 were lower during the months when delta was the dominant variant (July/August 2021) among COVE participants vaccinated more recently. Analysis of COVID-19 cases from the open-label phase of the COVE study is ongoing.

Competing Interest Statement

Dr. Baden reports being funded by the NIH to conduct clinical trials in collaboration with Crucell/Janssen and Moderna; Dr. El Sahly reports grants from National Institutes of Health during the conduct of the study; Dr. Follmann has nothing to disclose; Dr. Neuzil, reports receiving grant support from Pfizer; Drs. August, Deng, Han, Leav, Talarico Pajon, Girard, Paila, Tomassini, Schodel, Zhou, Das and Miller, and Ms Clouting and Fortier and Mr Zhao, report being employees of Moderna, Inc. and may hold stock/stock options in the company.

Clinical Trial

clinicalTrials.gov NCT04470427

Funding Statement

Moderna Inc. Moderna, Inc. Also supported by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (contract 75A50120C00034) and by the National Institute of Allergy and Infectious Diseases (NIAID). The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI 68614HVTN), the Statistics and Data Management Center (UM1 AI 68635), the HVTN Laboratory Center (UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI 68636), and the Infectious Diseases Clinical Research Consortium leadership group 5 (UM1 AI148684-03.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial is conducted in accordance with the International Council for Technical Requirements for Registration of Pharmaceuticals for Human Use, Good Clinical Practice Guidance, and applicable government regulations. The central Institutional Review Board/Ethics Committee, Advarra, Inc., 6100 Merriweather Drive, Columbia, MD 21044 approved the protocol and consent forms. All participants provided written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

As the trial is ongoing, access to patient-level data and supporting clinical documents with qualified external researchers may be available upon request and subject to review once the trial is complete.

https://www.ncbi.nlm.nih.gov/pubmed/33378609

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Kathleen M. Neuzil, Allison August, Heather Clouting, Gabrielle Fortier, Weiping Deng, Shu Han, Xiaoping Zhao, Brett Leav, Carla Talarico, Bethany Girard, Yamuna D. Paila, Joanne E. Tomassini, Florian Schödel, Rolando Pajon, Honghong Zhou, Rituparna Das, Jacqueline Miller
medRxiv 2021.09.17.21263624; doi: https://doi.org/10.1101/2021.09.17.21263624
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Kathleen M. Neuzil, Allison August, Heather Clouting, Gabrielle Fortier, Weiping Deng, Shu Han, Xiaoping Zhao, Brett Leav, Carla Talarico, Bethany Girard, Yamuna D. Paila, Joanne E. Tomassini, Florian Schödel, Rolando Pajon, Honghong Zhou, Rituparna Das, Jacqueline Miller
medRxiv 2021.09.17.21263624; doi: https://doi.org/10.1101/2021.09.17.21263624

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)